Healthcare Business

Is This the Death of Versartis?

Versartis Inc. (NASDAQ: VSAR) shares absolutely cratered on Friday after the firm announced results from its late-stage Velocity clinical trial of somavaratan in pediatric growth hormone deficiency (GHD). While Versartis might ...
Read Full Story »

FDA Crashes Down on Intercept’s Deadly Drug

Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) shares tumbled on Thursday after it came to light that the U.S. Food and Drug Administration (FDA) had issued a warning about the firm’s liver ...
Read Full Story »

Can BioCryst Turn Itself Around With This FDA Approval?

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) saw its shares make a handy gain in Thursday's premarket after the firm received an update from the U.S. Food and Drug Administration (FDA). This ...
Read Full Story »

Zai Lab Announces Potential Pricing for IPO

Zai Lab has filed an amended F-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price its 8 million ...
Read Full Story »

Why Alnylam Pharmaceuticals Is Wednesday’s Top Stock

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) saw its shares make a handy gain on Wednesday after the firm gave an update on its late-stage trial in patients with hereditary ATTR amyloidosis ...
Read Full Story »

MediWound Secondary Capitalizes on 2017 Success

MediWound Ltd. (NASDAQ: MDWD) saw its shares back off early on Tuesday after the company announced the pricing of its secondary offering. Biotech companies may attempt a secondary offering after ...
Read Full Story »

Will Dimension Therapeutics Take the New and Bigger Buyout Offer?

Dimension Therapeutics Inc. (NASDAQ: DMTX) saw one of the largest gains on the day after it came to light that the company received an acquisition offering from Ultragenyx Pharmaceutical Inc. ...
Read Full Story »

Deciphera Pharma Takes Another Step Closer to IPO

Deciphera Pharmaceuticals has registered an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company expects to price its 6.25 million ...
Read Full Story »

Pluristem Wins Key FDA Approval

Shares of Pluristem Therapeutics Inc. (NASDAQ: PSTI) saw a handy gain early Monday after the company said it had received a key update from the U.S. Food and Drug Administration (FDA). Essentially the ...
Read Full Story »

Why Nabriva Shares Are Doubling

Nabriva Therapeutics PLC (NASDAQ: NBRV) watched its shares more than double to kick off the week after the firm announced results from its late-stage trial in patients with community-acquired bacterial ...
Read Full Story »

Nightstar Therapeutics Announces Potential Pricing for IPO

Nightstar Therapeutics PLC has registered an amended F-1 form with the U.S. Securities and Exchange Commission (SEC). The company intends to price its 5.36 million American depositary shares (ADSs) in ...
Read Full Story »

T2 Biosystems Prices Secondary Offering

T2 Biosystems Inc. (NASDAQ: TTOO) saw its shares drop handily early on Friday after the firm announced that it would be pricing its secondary offering. The company is offering 4.375 ...
Read Full Story »

Krystal Biotech Gears Up for IPO

Krystal Biotech has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company expects to price its 3 million ...
Read Full Story »

Why Pfizer Is Pushing the Dow to All-Time Highs

Although the markets were mixed on Thursday, major drug manufacturers proved to be one of the more positive segments on the day. In fact, Pfizer Inc. (NYSE: PFE), Merck & ...
Read Full Story »

What You Need to Know About the Tenet Healthcare Sale

Tenet Healthcare Corp. (NYSE: THC) watched its shares make a handy gain early on Thursday after The Wall Street Journal announced that it was exploring the possibility of a sale. ...
Read Full Story »